A large number of studies have observed changes in the levels of ApoA1 and ApoB in patients with schizophrenia, with mixed results, such as elevated ApoA1 [31, 35, 36] or ApoB [37–39], which can be used as biomarkers of schizophrenia [39] as well as decreased ApoA1 [38, 40] or ApoB [36]. This evidence concerns the gene APOB and schizophrenia.